Navigation Links
GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
Date:3/26/2013

OXFORD, England, March 26, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its cardiac surgery intensive care trial and plans for CE mark testing at two leading MedTech conferences this spring. GlySure CEO Christopher Jones will speak at the inaugural Biovision Investor Conference on March 26th, 2013 in Lyon, France, and at the Investment In Innovation (IN³) Medical Device 360° Conference on April 17th, 2013 in Dublin, Ireland.

Studies have shown that inadequate post-operative blood sugar control in heart surgery patients is associated with an increased risk of major complications and death. GlySure recently completed a trial of its CBGM system on cardiac surgery patients.  The study revealed GlySure's technology can be used to continuously measure glucose levels with an extremely high degree of accuracy and repeatability across two-to-five days of a patient's stay in ICU, which is key to effectively implementing TGC.

At the Biovision Investor Conference and IN³ Medical Device 360° Conference, Jones will share results of GlySure's cardiac surgery ICU trial and outline the company's plans for CE regulatory trials, which are set to commence this Spring.

Biovision has selected GlySure as one of 35 life science companies to present to its forum of international capital investors and large healthcare companies seeking partnerships and innovation, while the producers of the (IN³) Medical Device 360° Conference have chosen GlySure as one of 35 early stage companies to appear before its global audience of VCs, top investors and corporate acquirers.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Media Contact: Kara Della Vecchia , KDV Communications, Inc. Tel: +1-508-314-3127. kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GlySure Earns ISO 13485 Certification
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
8. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
9. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
11. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:2/24/2017)... , Feb 24, 2017 Research and Markets has ... - 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis and Strategies ... market. The research answers the following questions: ... attributes? How are they positioned in the Global Hemophilia market? ...
(Date:2/24/2017)... Feb. 24, 2017  In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Tuesday, March 14, 2017 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
Breaking Medicine Technology:
(Date:2/24/2017)... , ... February 24, 2017 , ... An in-depth computational ... the University of Pittsburgh points to eight genes that may explain why susceptibility to ... to the results of a study published today in the journal npj Schizophrenia. ...
(Date:2/24/2017)... ... ... Smart Machine Age is here, and it’s disrupting everything. Not only could it drive ... United States may be taken over by technology in the next five to fifteen ... colleagues is drawing to a close. Success will belong to those who can quiet ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... disabilities, it is so critically important that we all are aware of our ... why Mediaplanet is proud to announce the launch of its newest edition of ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal ... Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, ... his attempts to overcome them. , Schanssema, initially unsure of the career path he ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for Palliative ... in or interested in palliative care education and research. The Symposium, “Innovate. Investigate. ... County San Diego on Sept. 28 and 29, 2017, on the campus of California ...
Breaking Medicine News(10 mins):